Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 44 of 79742 for:    subjects

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (GamaSTAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03351933
Recruitment Status : Completed
First Posted : November 24, 2017
Last Update Posted : September 24, 2018
Sponsor:
Information provided by (Responsible Party):
Grifols Therapeutics LLC

Brief Summary:

This is a single center, open-label, single-arm study in which approximately 28 Hepatitis A virus (HAV)-seronegative healthy subjects will be enrolled. There will be a screening period of up to 28 days during which subjects will be screened for enrollment in the study.

Healthy subjects will receive a single intramuscular (IM) dose of GamaSTAN (0.2 mL/kg), followed by a pharmacokinetic (PK) sampling period of 150 days (approximately 5 half-lives). The protective levels of anti-HAV antibodies will be assessed up to 60 days after the administration of GamaSTAN. A PK curve will be obtained during the PK sampling period.


Condition or disease Intervention/treatment Phase
Anti-Hepatitis A Antibody Levels in Heathy Subjects Biological: Immune Globulin (Human) Phase 4

Detailed Description:

This is a single center, open-label, single-arm study design, in which approximately 28 subjects will receive the same study treatment (0.2 mL/kg dose via IM injection). There is no reference therapy in this study.

The study will be explained to each subject prior to the subject providing written informed consent. All subjects will be screened to ensure that all the inclusion criteria and none of the exclusion criteria are met.

A sufficient number of healthy male and female subjects will be qualified by screening assessments and procedures for reporting to the clinical site on Day -1. The healthy subjects will receive a single IM dose of GamaSTAN (0.2 mL/kg) on Day 1. Subjects will be discharged from the clinic on Day 2, following the scheduled assessments and procedures, and will return to the clinical site for the remaining ambulatory PK samples and safety monitoring, and again for the final visit (Day 150).

The total duration of study participation for subjects who complete the study will be approximately 178 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects
Actual Study Start Date : October 31, 2017
Actual Primary Completion Date : April 27, 2018
Actual Study Completion Date : July 19, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Immune Globulin (Human) GamaSTAN
The healthy subjects will receive a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
Biological: Immune Globulin (Human)
A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) will be administered in healthy subjects.
Other Name: GamaSTAN




Primary Outcome Measures :
  1. Percentage of subjects maintaining protective anti- HAV antibody levels [ Time Frame: Day 60 ]
    Percentage of subjects maintaining anti-HAV antibody levels ≥10 mIU/mL up to Day 60 following study treatment administration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male subjects from 18 to 55 years of age, inclusive, or female subjects from 18 to 65 years of age, inclusive
  2. Subjects with a body mass index (BMI) of 18.5 to 29.9 kg/m2
  3. Body weight greater than or equal to 50 kg at screening
  4. Subjects willing and able to provide written informed consent
  5. Subjects in good health in the judgment of the Investigator, as determined by medical history, physical examination, vital signs, ECG and laboratory assessments
  6. A female study subject must meet one of the following criteria:

    1. If a female of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to study treatment administration and during the entire study duration. An acceptable method of contraception includes one of the following:

      • Abstinence from heterosexual intercourse (i.e. when abstinence is the preferred and usual lifestyle of the subject; periodic abstinence is not acceptable)
      • Non-estrogen containing hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
      • Intrauterine device without hormones
      • Condom with spermicide
      • Diaphragm or cervical cap with spermicide
      • Vasectomized partner (minimum 6 months since vasectomy prior to study treatment administration)
    2. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses prior to study treatment administration)
  7. A male study subject must agree to use one of the accepted contraceptive regimens during the entire study duration;

    • Abstinence from heterosexual intercourse
    • Female partner with condom with spermicide used by male study subject
    • Female partner of non-childbearing potential
    • Male sterilization (if proof of sterilization is not provided, the subject must agree to use one of the above accepted contraceptive methods)
  8. A male study subject must agree not to impregnate a female or donate sperm during the entire study duration

Exclusion Criteria:

  1. Subject vaccinated against HAV, as documented the in medical history at the screening visit
  2. Subject with positive anti-HAV antibodies in blood sample at the screening visit
  3. Subject who previously received any type of IG, including HAV IG within the past 12 months prior to study treatment administration
  4. Subject with prolonged International Normalized Ratio (INR) or activated partial thromboplastin time (aPTT) at the screening visit
  5. Subject with a platelet count below 100×109/L at the screening visit
  6. Subject suffering from some acute or chronic medical, surgical or psychiatric significant condition or laboratory abnormality at the screening visit or prior to study treatment administration that, according to Investigator judgement, may increase the risk associated with study participation or study treatment administration, or may interfere with the successful completion or interpretation of the study results
  7. Subject with a history of the following: angioedema, cardiac arrhythmia, angina pectoris, myocardial infarction, cerebrovascular accident, cardiac failure, thrombotic events, embolism, coagulopathy, diabetes mellitus, hyperlipidaemia, nephrotic syndrome, acute renal injury, chronic obstructive pulmonary disease, asthma, hepatic disease, reticuloendothelial system dysfunction, or nervous system disorder
  8. Subject with known personal or family history of abnormal bleeding episodes
  9. Subject not willing to receive study treatment via IM route of administration or unable to receive study treatment via IM route of administration
  10. Subject with cardiovascular risk factors based on medical history: active tobacco smoking and/or ongoing diabetes mellitus at the screening visit
  11. Subject with thrombosis risk factors: prolonged immobilization within 2 months prior to the screening visit, history of venous or arterial thrombosis, use of estrogens (30 days prior to the study drug administration), indwelling central vascular catheters and hyperviscosity or hypercoagulable states
  12. Subject with known history of hypersensitivity/allergic reaction to blood/plasma products
  13. Subject with known selective IgA deficiency (with or without antibodies to IgA)
  14. Subject who received any plasma-derived product infusion within 12 months prior to study treatment administration
  15. Subject who received a blood or plasma transfusion within 12 months prior to study treatment administration
  16. Subject with systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg at the screening visit and prior to treatment administration
  17. Subject with anemia (hemoglobin <12 g/dL in women and 13 g/dL in men) at the screening visit
  18. Subjects with proteinuria (>1+ on urine dipstick), blood urea nitrogen (BUN) or creatinine greater than the upper limit of normal at the screening visit
  19. Subject with liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT] and gamma-glutamyl transferase [GGT]) levels greater than the upper limit of normal at screening visit
  20. Subject who received any dose of parenteral, oral, or inhaled corticosteroids, immunosuppressants, or immunomodulators within 6 weeks prior to the screening visit
  21. Subject who received any live virus vaccine within five months prior to the screening visit
  22. Subject not willing to postpone receiving any live virus vaccines until 6 months after receiving IP
  23. Currently receiving any anti-viral treatment, regardless of the route of administration
  24. Subject with virus safety laboratory results (serology and/or nucleic acid amplification technology [NAT]) indicative of a current infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or parvovirus B19 (B19V) at the screening visit
  25. Participated in another clinical trial within 30 days prior to the screening visit or has received any IPs within 3 months prior to the screening visit
  26. Positive urine drug panel testing at the screening visit or prior to study treatment administration
  27. Known or suspected abuse of alcohol, opiates, psychotropic agents or other drugs or chemical substances; or has done so in the 12 months prior to the screening visit
  28. In the opinion of the Investigator, the subject may have compliance problems with the protocol and the procedures of the protocol
  29. Subject who has already been included in a previous group for this clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03351933


Locations
Layout table for location information
United States, Kansas
Vince & Associates Clinical Research, Inc.
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Grifols Therapeutics LLC

Layout table for additonal information
Responsible Party: Grifols Therapeutics LLC
ClinicalTrials.gov Identifier: NCT03351933     History of Changes
Other Study ID Numbers: GC1703
First Posted: November 24, 2017    Key Record Dates
Last Update Posted: September 24, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis
Hepatitis A
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Immunoglobulins
Antibodies
gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs